Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability
Date:3/31/2009

DETROIT, March 31 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD), a generic pharmaceutical company, announced today that all tablets of Caraco brand Digoxin, USP, 0.125 mg, and Digoxin, USP, 0.25 mg, distributed prior to March 31, 2009, which are not expired and are within the expiration date of September, 2011, are being voluntarily recalled to the consumer level. The tablets are being recalled because they may differ in size and therefore could have more or less of the active ingredient, digoxin. The recalled tablets were manufactured by Caraco Pharmaceutical Laboratories, Ltd. This recall is being conducted with the knowledge of the Food and Drug Administration.

Digoxin is a drug product used to treat heart failure and abnormal heart rhythms. It has a narrow therapeutic index and the existence of higher than labeled dose may pose a risk of digoxin toxicity in patients with renal failure. Digoxin toxicity can cause nausea, vomiting, dizziness, low blood pressure, cardiac instability, and bradycardia. Death can also result from excessive digoxin intake. A lower than labeled dose may pose a risk of lack of efficacy potentially resulting in cardiac instability. Consequently, as a precautionary measure, Caraco is recalling these tablets to the consumer level to minimize any potential risk to patients.

Consumers with the products with the following NDC codes that are within expiration should return these products to their pharmacy or place of purchase.

    Product Identification
    Caraco Digoxin 0.125 mg is a scored     Caraco Digoxin 0.25 mg is a scored
    round biconvex yellow tablet            round biconvex white tablet
    imprinted with "437"                    imprinted with "441"

    NDC Numbers:
    Digoxin Tablets, USP, 0.125 mg          Digoxin Tablets, USP, 0.25 mg
    57664-437-88 (100-count)                57664-441-88 (100-count)
    57664-437-18 (1000-count)               57664-441-18 (1000-count)

Patients using Caraco's Digoxin tablets, USP, 0.125 mg or 0.25 mg, who have medical questions should contact their healthcare provider for additional instructions or guidance.

Retailers who have this product should return the product to their place of purchase. Retailers can call Caraco customer service at (800) 818-4555, Monday through Friday, 8:00 a.m. - 5:00 p.m. EDT, for instructions on how to return the affected product or for any other inquiries related to this action.

Any adverse reactions experienced with the use of all affected product, and/or quality problems should also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by Fax at 1-800-FDA-0178, by mail at Med Watch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009
2. Caraco Pharmaceutical Laboratories, Ltd. to Announce Third Quarter of Fiscal Year 2009 Results on January 29, 2009
3. Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter
4. Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter
5. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
6. Caraco Pharmaceutical Laboratories, Ltd. Reaches Agreement with Labor Union
7. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
10. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
11. Caraco Pharmaceutical Laboratories Ltd. Wins Summary Judgment on Generic Ultracet(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South ... TX area 24 Hours a day. , The Emergency Room opened ... “We’ve been open four months now and things are running smoothly,” said Aaron Braun, ...
(Date:7/24/2017)... Los Angeles, CA (PRWEB) , ... July 24, 2017 , ... ... that will spotlight doctors and the cosmetic surgeries they perform on a daily basis. ... in performing the cosmetic surgery procedures they specialize in at their practices. , ...
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor ... neurological condition called essential tremor (ET). The seminar will take place on Saturday, Aug. ... Blvd., Independence, OH. The program will run from 9 a.m. to 12 p.m., with ...
(Date:7/24/2017)... ... ... people are taking more steps to protect themselves from sunburn, half of all adults and ... the past year. It’s common and people have been dealing with them since the dawn ... conscientious of the risks that accompany sunburns. , The team at AloeVera.com , a ...
(Date:7/24/2017)... ... 24, 2017 , ... A new report released today by ... sleep health care at scale, indicates record-breaking adherence results for the company’s obstructive ... airway pressure (PAP) therapy, the most widely utilized treatment for OSA, typically range ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017  BDI Group ... and patient support services organization serving specialty pharmacies, ... the launch of four significant, value-added member programs ... insights, better manage reimbursement and improve access and ... factor therapies. ...
(Date:7/5/2017)... Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves to ... progress molecular radiotherapy imaging. In molecular radiotherapy (MRT) ... quantify the radiation absorbed by those patients undergoing treatment. As ... radiotherapy treatment has been available — that is, until now. ... ...
(Date:7/1/2017)... , June 30, 2017 Zimmer Biomet Holdings, Inc. ... and earnings conference call will be broadcast live over the ... Time.  A news release detailing the quarterly results will be ... the conference call. The live audio webcast can ... http://investor.zimmerbiomet.com . It will be archived for replay following the ...
Breaking Medicine Technology: